Wednesday, January 17, 2024 11:04:22 AM
The applicant, Merck Sharp, & Dohme, submitted a Preliminary/final Land Development application to the Township on November 17, 2023 for the Merck West Point Campus, located at 770 Sumneytown Pike. The applicant proposes to construct a 110,600 square foot building on a footprint of 40,300 Square feet. The building will be 3 floors; 1st floor consisting of 2 loading docks, 2nd floor consisting of sample testing labs, cold storage, and offices, the 3rd floor consisting of sample testing labs, office space, and shell space. The building exterior will be insulated metal clad panels with glass, located 850 feet from Sumneytown Pike and 800 feet from West Point Pike. The proposal also addressed on-site parking, connection to local in-place facilities, and landscaping. This new building will be occupied by 180 staff members, a mix of transfers and new employees.
https://www.uppergwynedd.org/sites/g/files/vyhlif1351/f/uploads/merck_b41_ld_approval.pdf
“The world is waiting for the next big thing — innovations that will help confront the tremendous burden of disease for patients. Addressing those diseases requires the kind of world-class, scientific exploration that we are pursuing.”
https://www.merck.com/stories/why-were-expanding-and-investing-in-our-research-and-discovery-efforts/
While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.”
https://www.fiercepharma.com/pharma/jpm24-merck-expects-over-20b-post-keytruda-sales-new-cancer-drugs-thanks-daiichi-adc-deal
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
